Nevertheless, the individual properties of ADMs may have a different effect on weight and glycemic level maintenance as the study by McIntyre et al. in 2005 indicated that long-acting SSRIs fluoxetine and nonselective hydrazine monoamine oxidase inhibitors (e.g., phenelzine) improved glycemic control and insulin sensitivity; however, noradrenergic ADMs (e.g., desipramine) caused hyperglycemia, and dual-mechanism ADMs (e.g., duloxetine and venlafaxine) did not affect glucose homeostasis [54]. The gene discussed is INS; the disease is Hyperglycemia.